PARIS – The bioresorbable vascular scaffold (BVS) Absorb and Xience drug-eluting stent (DES) show similar clinical outcomes at 7-year follow-up in the final results from the COMPARE-ABSORB trial. Pieter C. Smits, MD, PhD, of the Maasstad Hospital, Rotterdam, The Netherlands, presented these results during a Hotline session on Wednesday at the EuroPCR Congress 2025. Patients who are at high risk for restenosis may benefit from resorbable scaffolds. Prior randomized controlled trials (RCTs) have investigated this in patients with ST-segment myocardial infarction (STEMI), acute non-STEMI, bifurcations, long lesions and chronic total occlusions (CTOs) The COMPARE-ABSORB trial sought to understand which patient groups would receive this benefit, specifically populations not included in former RCTs. A total of 1,670 patients were randomized to receive the Absorb (Abott) BVS (n=848, n=802 at 7-year follow-up) or the Xience (Abbott) DES (n=822, n=784 at 7-year follow-up). At 30-days follow-up, both groups had similar TLF event rates. At the 3-year follow-up, the Absorb group had significantly higher rates of target lesions revascularizations (TLF), demonstrating the superiority of the Absorb stent at 3-years. Reported in this study, the 7-yer follow-up showed 6.7% of Absorb and 5.9% of Xience patients had TLF (p=0.53), 2.3% of Absorb and 2.8% of Xience patients died (p=0.58), 2.0% of Absorb and 2.2% of Xience patients had target vessel myocardial infarction (TV-MI) and 4.4% of Absorb and 2.2% of Xience patients had clinically driven target lesion revascularization (CT-TLR). Overall, the 7-year follow-up of the COMPARE-ABSORB trial showed no significant differences in outcomes between the Absorb BVS and Xience DES. Image Credit: Copyright EuroPCR 2025 Image Caption: Pieter C. Smits, MD, PhD, speaks during a press conference on Tuesday at EuroPCR Congress 2025 in Paris.